We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

34 hedge funds and large institutions have $2.41M invested in SAB Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

0.05% less ownership

Funds ownership: 0.79% → 0.73% (-0.05%)

11% less funds holding

Funds holding: 38 → 34 (-4)

27% less capital invested

Capital invested by funds: $3.28M → $2.41M (-$872K)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

Holders
34
Holders Change
-4
Holders Change %
-10.53%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
2
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PFO
Pathstone Family Office
New Jersey
+$372K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$41K
3
Osaic Holdings
Osaic Holdings
Arizona
+$20.4K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$10.4K
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.72K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$69.7K
2
SOS
Silver Oak Securities
Tennessee
-$43K
3
Prudential Financial
Prudential Financial
New Jersey
-$30K
4
VF
Virtu Financial
New York
-$21K
5
Two Sigma Investments
Two Sigma Investments
New York
-$20.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Baird Financial Group
26
Baird Financial Group
Wisconsin
$6.3K – – –
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$3K -$206 -28 -5%
GI
28
GS Investments
Minnesota
$1.26K – – –
JP Morgan Chase
29
JP Morgan Chase
New York
$584 +$37 +5 +6%
HI
30
Harbour Investments
Wisconsin
$315 – – –
Fidelity Investments
31
Fidelity Investments
Massachusetts
$216 +$250 +34 New
Wells Fargo
32
Wells Fargo
California
$169 +$15 +2 +8%
NA
33
NewEdge Advisors
Louisiana
$91 – – –
Qube Research & Technologies (QRT)
34
Qube Research & Technologies (QRT)
United Kingdom
$43 +$51 +7 New
V
35
Veritable
Delaware
– -$420K -50,651 Closed
BCM
36
Bridgeway Capital Management
Texas
– -$69.7K -8,400 Closed
SOS
37
Silver Oak Securities
Tennessee
– -$43K -5,189 Closed
Prudential Financial
38
Prudential Financial
New Jersey
– -$30K -3,620 Closed
Two Sigma Investments
39
Two Sigma Investments
New York
– -$20.8K -2,509 Closed
VF
40
Virtu Financial
New York
– -$21K -2,490 Closed
TSS
41
Two Sigma Securities
New York
– -$10.7K -1,287 Closed
1
2

SABS Hedge Fund Activity: Q3 2023 in Review

34 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q3 2023, worth a combined $2.41M — down 27% from $3.28M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SABS and 3 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 7 added.

The largest buyer was Pathstone Family Office, opening a new position worth an estimated $372K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $69.7K sold.

  • 34 institutional investors held SAB Biotherapeutics (SABS) as of Q3 2023, down from 38 in Q2 2023.
  • Funds reported $2.41M of SAB Biotherapeutics stock for Q3 2023, down 27% quarter-over-quarter.
  • 3 funds opened new SAB Biotherapeutics positions in Q3 2023 and 7 closed out, a net change of -4 holders.
  • The largest SAB Biotherapeutics buyer in Q3 2023 was Pathstone Family Office, an estimated $372K added.
  • The largest SAB Biotherapeutics seller in Q3 2023 was Bridgeway Capital Management, an estimated $69.7K sold.

Based on aggregated 13F filings for Q3 2023.